PAX4 Antibody

What is PAX4 and why is it important in diabetes research?

PAX4 (Paired Box 4) is a paired-box transcription factor that functions as a key regulator of pancreatic islet cell growth and differentiation. It plays a critical role in the development of insulin-producing beta cells and is essential for normal pancreatic islet development . PAX4 acts as a transcriptional repressor that binds to common elements in the glucagon, insulin, and somatostatin promoters, often competing with PAX6 for these binding sites . Mutations in PAX4 are associated with several forms of diabetes, including maturity-onset diabetes of the young type 9 (MODY9), ketosis-prone diabetes (KPD), and can contribute to susceptibility to both type 1 and type 2 diabetes . This makes PAX4 a significant target for researchers investigating pancreatic development, beta-cell function, and diabetes pathogenesis.

How does PAX4 influence beta-cell development and function?

PAX4 exerts multiple effects on beta-cell biology:

• Development regulation: PAX4 is crucial for the differentiation of endoderm-derived endocrine pancreas, working alongside PAX6 to coordinate proper islet cell development .

• Transcriptional repression: PAX4 functions primarily as a repressor that competes with PAX6 for binding sites in the promoters of key pancreatic hormones .

• Cell proliferation and survival: Research has demonstrated that PAX4 can induce beta-cell proliferation, with studies showing a 3.5-fold increase in BrdU labeling of beta-cells expressing PAX4 compared to controls . This effect appears to be specific to PAX4, as overexpression of other transcription factors like PAX6 and neurogenin3 did not affect proliferation .

• Anti-apoptotic effects: PAX4 has been shown to promote beta-cell survival through induction of anti-apoptotic genes like bcl-xl, contributing to maintenance of beta-cell mass .

• Metabolic regulation: PAX4 influences mitochondrial function, ATP production, and calcium homeostasis, which affects glucose-induced insulin secretion .

What criteria should researchers consider when selecting a PAX4 antibody?

When selecting a PAX4 antibody, researchers should consider:

• Target region: Different antibodies target different regions of PAX4. Some target the middle region (amino acids 171-200) , while others may target other domains. Consider which region is most relevant to your research question.

• Species reactivity: Verify compatibility with your experimental model. Available PAX4 antibodies show varying reactivity profiles:

  • Some react with human, mouse, and rat samples

  • Others have broader reactivity including dog, cow, rabbit, guinea pig, and horse

• Isoform recognition: PAX4 has multiple isoforms (38, 30, and 37 kDa). Confirm whether the antibody recognizes all or specific isoforms. Some antibodies are 100% homologous to all three isoforms .

• Application compatibility: Select an antibody validated for your specific application:

  • Western Blot (WB): Typically used at 1:500-1:2000 dilution

  • Immunohistochemistry (IHC): Used at 1:10-1:50 dilution

  • Immunofluorescence (IF): Validated for cellular localization studies

  • ELISA: For quantitative protein detection

  • Flow Cytometry: For cellular analysis at 1:10-1:50 dilution

• Host species: Consider the host species (rabbit, mouse) to avoid cross-reactivity issues in multi-label experiments .

How can researchers validate PAX4 antibody specificity?

To validate PAX4 antibody specificity:

• Positive controls: Use tissues or cell lines known to express PAX4, such as:

  • DAUDI or Ramos cells

  • Human tonsil, lymph node, or pancreatic tissue

  • MIN6, βTC, or NIT1 islet β cell lines

• Negative controls: Include samples where primary antibody is replaced with PBS or pre-immune serum .

• Western blot validation: Verify molecular weight (approximately 38 kDa for the main isoform) in positive control lysates such as HeLa, K562, or pancreatic tissue .

• Peptide competition assay: Pre-incubate the antibody with immunizing peptide to confirm binding specificity through signal abrogation.

• Genetic validation: If possible, compare staining between wild-type and PAX4 knockout samples. Recent research has generated PAX4-/- hiPSC lines that could serve as valuable negative controls .

• Cross-species validation: Confirm similar staining patterns across multiple species where PAX4 is conserved.

What are the optimal conditions for using PAX4 antibodies in Western blotting?

For optimal Western blot detection of PAX4:

• Sample preparation:

  • For cell lines: Lyse cells in a buffer containing protease inhibitors (e.g., HeLa, K562 cells show good detection)

  • For tissues: Fresh pancreatic tissue shows better results than other tissues

• Protein loading: Load 20-50 μg of total protein per lane for optimal detection.

• Antibody dilution: Most PAX4 antibodies work optimally at dilutions of 1:1000-1:2000 for Western blot .

• Detection method: Secondary antibody conjugated to HRP with ECL detection yields clear bands.

• Expected results: The main PAX4 isoform appears at approximately 38 kDa, with additional isoforms possibly appearing at 30 kDa and 37 kDa .

• Blocking conditions: 5% non-fat dry milk in TBST for 1 hour at room temperature typically provides optimal blocking.

• Storage conditions: Store antibody aliquots at -20°C or colder to avoid repeated freeze-thaw cycles that may diminish activity .

What protocols are recommended for using PAX4 antibodies in immunohistochemistry?

For optimal IHC detection of PAX4:

• Tissue preparation:

  • Formalin-fixed, paraffin-embedded (FFPE) tissues require antigen retrieval

  • Heat-mediated antigen retrieval in 10 mM Tris with 1 mM EDTA (pH 9.0) for 45 minutes at 95°C followed by cooling at room temperature for 20 minutes

• Antibody dilution: Use PAX4 antibodies at 1:10-1:50 dilution for IHC applications .

• Detection method:

  • For chromogenic detection: Use appropriate HRP-conjugated secondary antibodies with DAB substrate

  • For fluorescent detection: Use fluorophore-conjugated secondary antibodies

• Incubation conditions: Incubate primary antibody for 30 minutes at room temperature or overnight at 4°C .

• Positive control tissues: Human tonsil, lymph node, or colon carcinoma show good PAX4 expression .

• Subcellular localization: PAX4 shows predominantly nuclear localization as expected for a transcription factor .

What approaches are effective for studying PAX4 in pancreatic islet cells?

For studying PAX4 in pancreatic islet cells:

• Islet isolation and culture:

  • Isolated rat and human islets of Langerhans maintain PAX4 expression and can be used for functional studies

  • Cultured islets can be transduced with adenoviral constructs harboring PAX4 cDNA to study effects of overexpression

• Cell proliferation analysis:

  • BrdU incorporation assays can measure PAX4-induced beta-cell proliferation

  • PAX4 overexpression increases beta-cell proliferation by approximately 3.5-fold compared to controls

• Expression analysis:

  • qPCR can detect PAX4 transcript levels, with expression notably present in pancreatic islets and beta-cell lines

  • Western blotting can confirm protein expression levels

• Functional assays:

  • Glucose-stimulated insulin secretion tests can assess the impact of PAX4 on beta-cell function

  • Mitochondrial function assays (ATP production, Ca2+ homeostasis) can evaluate PAX4's effect on metabolic pathways

• Protein-DNA interaction studies:

  • Electrophoretic mobility shift assays (EMSA) with the C2 element of the rat glucagon promoter can demonstrate PAX4 binding

  • Super-shift assays using PAX4 antiserum can confirm specific binding

What explains multiple bands in Western blots when using PAX4 antibodies?

Multiple bands in PAX4 Western blots may be attributed to:

• Multiple isoforms: PAX4 has three documented isoforms (38, 30, and 37 kDa). Some antibodies recognize all three isoforms .

• Post-translational modifications: PAX4 undergoes phosphorylation at specific sites (T26 and T64), which can alter migration patterns .

• Proteolytic degradation: Sample preparation without adequate protease inhibitors may result in degradation products.

• Non-specific binding: Some antibodies may cross-react with other proteins, particularly other PAX family members which share structural similarities.

• Alternative splicing: PAX4 transcripts can undergo alternative splicing, producing variant proteins. For example, isoform 2 appears to function as a dominant negative form antagonizing PAX4 transcriptional activity .

To address multiple bands:

• Use positive controls with known PAX4 expression

• Compare band patterns across multiple tissues/cell types

• Perform peptide competition assays to identify specific bands

• Consider using another PAX4 antibody targeting a different epitope to confirm results

How can researchers troubleshoot weak or absent signals in PAX4 detection?

When encountering weak or absent PAX4 signals:

• Sample considerations:

  • Confirm PAX4 expression in your sample (PAX4 is predominantly expressed in pancreatic islet β cells)

  • Use positive controls such as DAUDI cells, human tonsil, or pancreatic tissue

  • PAX4 may have developmental stage-specific expression

• Antibody optimization:

  • Titrate antibody concentration (try 1:500 if 1:1000 yields weak signals)

  • Extend incubation time (overnight at 4°C rather than 1-2 hours)

  • Test different antibody clones or suppliers

• Protocol adjustments:

  • For Western blot: Increase protein loading (50-75 μg)

  • For IHC: Optimize antigen retrieval (try 10 mM Tris with 1 mM EDTA, pH 9.0)

  • For IF: Test different fixation methods (4% PFA vs. methanol)

• Detection enhancements:

  • Use signal amplification systems (TSA/tyramide)

  • Try more sensitive substrates for HRP detection

  • For fluorescence, use high-sensitivity fluorophores

• Storage and handling:

  • Aliquot antibodies to avoid freeze-thaw cycles

  • Store at recommended temperatures (-20°C or colder)

  • Check antibody expiration date

How can researchers distinguish between specific PAX4 staining and background in immunofluorescence?

To distinguish specific PAX4 staining from background:

• Critical controls:

  • Negative control: Omit primary antibody but include all other steps

  • Isotype control: Use non-specific IgG from the same species as the primary antibody

  • Peptide competition: Pre-incubate antibody with immunizing peptide

  • Biological negative control: Use tissue known not to express PAX4

• Signal characteristics:

  • PAX4 should show nuclear localization as expected for a transcription factor

  • Signal intensity should correlate with known expression patterns (higher in β cells)

  • Staining should be absent in negative control samples

• Background reduction strategies:

  • Optimize blocking (try 5% BSA or 10% serum from secondary antibody host species)

  • Include 0.1-0.3% Triton X-100 for better nuclear penetration

  • Increase washing duration and frequency (3-5 washes of 5-10 minutes each)

  • Reduce primary antibody concentration if background is high

• Multi-channel validation:

  • Co-stain with cell-type markers (insulin for β cells)

  • Use DAPI to confirm nuclear localization

  • Check for signal in non-relevant channels (autofluorescence check)

How can PAX4 antibodies be used to study diabetes pathogenesis?

PAX4 antibodies can be valuable tools for diabetes research:

• Genetic variant analysis:

  • Study the effects of diabetes-linked PAX4 mutations such as R129W and Y186X

  • Research indicates these mutations result in attenuated responses compared to wild-type PAX4

  • PAX4 loss-of-function mutations may lead to gradual loss of insulin-producing cells

  • Recent work with PAX4-/- hiPSC lines shows derepression of alpha cell genes (ARX, GCG, TTR) and altered endocrine cell differentiation

• Beta-cell mass regulation:

  • Examine how PAX4 influences beta-cell proliferation and protection against apoptosis

  • Studies show PAX4 overexpression promotes beta-cell proliferation by 3.5-fold

  • Compare PAX4 expression between healthy and diabetic pancreatic samples

• Pancreatic development studies:

  • Track PAX4 expression during pancreatic organogenesis

  • Investigate interactions between PAX4 and other transcription factors (PAX6)

  • Study how PAX4 regulates endocrine cell fate decisions

• Functional assessments:

  • Correlate PAX4 expression with metrics of beta-cell function like insulin secretion

  • Research found that PAX4 alters mitochondrial function, ATP production, and Ca2+ homeostasis, affecting glucose-induced insulin secretion

  • Measure beta-cell function using the disposition index (DI) in relation to PAX4 status

• Therapeutic target validation:

  • Screen for compounds that modulate PAX4 expression or activity

  • Study whether PAX4 restoration or modulation can improve beta-cell function or mass

What are the methodological considerations for using PAX4 antibodies in stem cell differentiation research?

When using PAX4 antibodies in stem cell research:

• Differentiation protocol monitoring:

  • Use PAX4 immunostaining to track pancreatic endocrine progenitor development

  • PAX4 expression can be used as a marker for beta-cell lineage commitment

  • Recent research has differentiated hiPSC lines into pancreatic beta-like cells (BLCs) and monitored PAX4 expression at the endocrine progenitor (EP) stage

• Temporal expression analysis:

  • Track PAX4 expression at different stages of differentiation

  • Combine with other markers (PDX1, NKX6.1, insulin) to characterize differentiation efficiency

  • PAX4 transcript levels can be analyzed at different stages (e.g., endocrine progenitor stage)

• Genetic manipulation strategies:

  • Use PAX4 antibodies to validate genetic modifications (overexpression, knockdown)

  • Recent research has generated PAX4 knockout hiPSC lines using CRISPR/Cas9, which can be differentiated into pancreatic lineages

  • Doxycycline-inducible adenoviral constructs harboring PAX4 cDNA can be used for controlled expression studies

• Lineage tracing:

  • Combine PAX4 staining with other endocrine markers to track cell fate

  • Recent studies have noted that PAX4 loss leads to derepression of other endocrine hormones (GCG, SST, GHRL, PPY)

  • PAX4 knockout cells showed altered endocrine cell development with increased polyhormonal (C-PEP+/GCG+) cells

• Functional assessment:

  • Correlate PAX4 expression with functional maturity of stem cell-derived beta cells

  • Assess insulin secretion in response to glucose challenges

  • Evaluate mitochondrial function and calcium handling

How can researchers investigate the role of PAX4 variants in diabetes pathogenesis?

To investigate PAX4 variants in diabetes:

• Variant characterization platforms:

  • Use hiPSC-based models to study PAX4 variants

  • Recent research has generated hiPSCs with various PAX4 genotypes including wildtype, heterozygous for p.Arg192His or p.Tyr186X, and homozygous for p.His192 allele

  • Multiple independent hiPSC lines should be used to account for line-to-line heterogeneity

• Functional genomics approaches:

  • Compare gene expression profiles between wildtype and PAX4 variant cells

  • Recent studies found that PAX4-/- lines show differential expression of alpha cell genes and altered endocrine differentiation

  • RNA-seq analysis can identify genes affected by PAX4 variants

• Cellular phenotyping:

  • Assess beta-cell function, proliferation, and survival in cells with PAX4 variants

  • The diabetes-linked mutant R129W elicits attenuated responses compared to wildtype PAX4

  • The p.Tyr186X variant showed elevated PAX4 transcript in endocrine progenitors, consistent with transcriptional compensation for the protein-truncating variant

• Pancreatic differentiation analysis:

  • Compare differentiation efficiency between wildtype and PAX4 variant stem cells

  • Track hormone expression (insulin, glucagon, somatostatin)

  • Monitor development of polyhormonal cells

• Clinical correlation:

  • Relate laboratory findings to clinical phenotypes in mutation carriers

  • Recent research found that family members with the PAX4 p.Tyr186X variant had markedly reduced beta-cell function as measured by the disposition index (DI)

  • Family members without diabetes who didn't carry the variant showed higher beta-cell function

What storage and handling practices ensure optimal PAX4 antibody performance?

To maintain PAX4 antibody performance:

• Storage conditions:

  • Store at -20°C for long-term stability (some antibodies can be stored at -80°C)

  • Most PAX4 antibodies are stable for 24 months when properly stored

  • Avoid repeated freeze-thaw cycles by preparing small aliquots upon receipt

• Buffer composition:

  • Many PAX4 antibodies are provided in PBS with 0.02-0.09% sodium azide

  • Some formulations include 50% glycerol for stability enhancement

  • Antibodies for immunohistochemistry may contain BSA in the formulation

• Working solution preparation:

  • Dilute antibodies in fresh buffer immediately before use

  • For Western blotting, dilute in 5% non-fat dry milk or BSA in TBST

  • For immunostaining, dilute in blocking buffer containing 1-5% BSA or serum

• Quality control parameters:

  • Review certificate of analysis for lot-specific information

  • Check appearance (should be clear without precipitation)

  • Consider testing each new lot against a previously validated lot

• Antibody alternatives:

  • For critical experiments, maintain stocks of PAX4 antibodies from different suppliers or clones

  • Consider antibodies targeting different epitopes for confirmation

  • Both rabbit polyclonal and mouse monoclonal PAX4 antibodies are available

How can researchers optimize multiplexed detection of PAX4 with other pancreatic markers?

For multiplexed detection of PAX4 with other markers:

• Antibody selection considerations:

  • Choose PAX4 antibodies raised in different host species than other target antibodies

  • If using rabbit anti-PAX4, select mouse antibodies for other targets

  • Ensure epitope compatibility with fixation and antigen retrieval methods

• Sequential staining approach:

  • For challenging combinations, perform sequential rather than simultaneous staining

  • Start with the weakest signal antibody followed by stronger ones

  • Use complete washing and blocking between rounds of staining

• Optimized marker combinations:

  • PAX4 (nuclear) + Insulin (cytoplasmic) to identify beta cells

  • PAX4 + PDX1 (nuclear) using different species antibodies and distinct fluorophores

  • PAX4 + Glucagon to distinguish alpha and beta cell populations

• Signal separation strategies:

  • Use well-separated fluorophores to minimize spectral overlap

  • Apply spectral unmixing for closely overlapping signals

  • Consider tyramide signal amplification for weak PAX4 signal

• Controls for multiplexed detection:

  • Single-stained controls for each antibody

  • Fluorescence-minus-one controls to assess bleed-through

  • Isotype controls for each host species used

Table of recommended marker combinations for pancreatic studies with PAX4: